The challenge of choosing in cardiovascular risk management
Publication year
2022Source
Netherlands Heart Journal, 30, 1, (2022), pp. 47-57ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Internal Medicine
Cardiology
Journal title
Netherlands Heart Journal
Volume
vol. 30
Issue
iss. 1
Page start
p. 47
Page end
p. 57
Subject
Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences; Radboudumc 6: Metabolic Disorders RIMLS: Radboud Institute for Molecular Life Sciences; Cardiology - Radboud University Medical Center; Internal Medicine - Radboud University Medical CenterAbstract
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. For many years guidelines have listed optimal preventive therapy. More recently, novel therapeutic options have broadened the options for state-of-the-art CV risk management (CVRM). In the majority of patients with CVD, risk lowering can be achieved by utilising standard preventive medication combined with lifestyle modifications. In a minority of patients, add-on therapies should be considered to further reduce the large residual CV risk. However, the choice of which drug combination to prescribe and in which patients has become increasingly complicated, and is dependent on both the absolute CV risk and the reason for the high risk. In this review, we discuss therapeutic decisions in CVRM, focusing on (1) the absolute CV risk of the patient and (2) the pros and cons of novel treatment options.
This item appears in the following Collection(s)
- Academic publications [245131]
- Electronic publications [132454]
- Faculty of Medical Sciences [93207]
- Open Access publications [106009]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.